• Home
  • Search Results
  • Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.

Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.

Bioconjugate chemistry (2015-01-30)
B Podobnik, B Helk, V Smilović, Š Škrajnar, K Fidler, S Jevševar, A Godwin, P Williams
ABSTRACT

The covalent attachment of poly(ethylene glycol) (PEG) to therapeutic proteins is a commonly used approach for extending in vivo half-lives. A potential limitation of this PEGylation strategy is the adverse effect of PEG on conjugate viscosity. Interferon-alpha (IFN) was conjugated via its N-terminal amino group by reductive amination to α-aldehyde functional comb-shaped PolyPEG polymers (50 and 70 kDa) and to linear PEG (30 kDa). In vitro potencies of the purified PEGylated IFN conjugates were measured by reporter gene assay using a HEK293P/ISRE-SEAP cell line. IFN levels were measured in rats following intravenous injection. Viscosities of various linear PEG and PolyPEG polymers along with the polymer-IFN conjugates were determined using a rotational rheometer with cone-and-plate geometry. In vitro potencies and half-lives of the PEGylated IFN conjugates were compared with those of the marketed branched PEG-IFN conjugate PEGASYS. Both PolyPEG-IFN conjugates retained a similar potency as that of the marketed comparator, whereas the linear PEG-IFN conjugate potency was greater. All conjugates showed extended half-lives compared to that of naked IFN, with the PolyPEG conjugates exhibiting the longest half-lives and the linear PEG conjugate, the shortest. Viscosity analysis showed that the linear PEG-IFN conjugate was over twice as viscous as both PolyPEG conjugates. Taken together, this work demonstrates the potential of PolyPEG conjugation to therapeutic proteins as a novel tool for optimizing pharmacokinetic profiles in a way that potentially allows administration of high-dose formulations because of lower conjugate viscosity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Copper(I) bromide, 98%
Sigma-Aldrich
Copper(I) bromide, 99.999% trace metals basis
Sigma-Aldrich
Copper(I) bromide, purum p.a., ≥98.0% (RT)
Sigma-Aldrich
Copper(I) bromide, AnhydroBeads, -10 mesh, 99.99% trace metals basis

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.